The dehydration of biopharmaceutical products through dr ying provides numerous benefits, including ease of handling and storage, reduction in transportation costs, and improved stability. Typically, the drying of biotherapeutics is accomplished through freeze-drying, however, the removal of water by lyophilization possesses several drawbacks, including lengthy drying times, low energy efficiency, and the high cost of purchasing and maintaining the equipment. Furthermore, freezedrying is a batch process which may be challenging to adapt and implement with the recent push for continuous manufacturing. These limitations have led to the search for next-generation drying technologies that can be applied to the manufacture of biotherapeutic products. Several alternative dr ying methods to freeze-dr ying have been developed and implemented in industries outside of pharmaceuticals, such as food and agriculture, and some are at an advanced state. With the aim of applying lessons learned from technologies in various industries, herein, we review several processing technologies with particular emphasis on the advantages and disadvantages of each in comparison to lyophilization and their potential to be adapted and utilized for drying biotherapeutic compounds.
Introduction
Biopharmaceuticals or biologics, distinct from small molecule pharmaceuticals, include a wide variety of therapeutic products derived from living organisms or produced using biotechnology, e.g., recombinant proteins, vaccines, blood components, cellular therapies, and gene therapies. Following the advent of recombinant DNA technology in the 1970s, the pharmaceutical industr y observed a shift in pipeline development from predominantly chemically synthesized drugs towards biologics.
The FDA approved the first protein-based biologic (recombinant insulin, Humulin) in 1982 and the first monoclonal antibody (-OKT-3) in 1986 (later withdrawn). Thereafter, there has been continual growth in the number of biopharmaceuticals on the market. The US and EU have seen a combined average of more than 10 new approvals every year since the mid-1990s [1] , which is in stark contrast to the total number of approvals prior to 1990, which was 9.
As the number of biopharmaceutical approvals and those in development continues to grow, the complexity has also increased. In the late 90's, recombinant proteins and monoclonal antibodies (mAbs) were at the frontline of innovation, offering many challenges associated with stabilizing their highly labile structures. Currently, the industry is faced with manufacturing antibody drug conjugates (ADCs), multi-valent polysaccharide-conjugate vaccines, and gene therapies, to name a few. The challenges associated with manufacturing these compounds are considerably greater, with the formulation scientist and process engineer having to extrapolate his/her basic knowledge of stabilization approaches for proteins to these novel modalities.
Removal of water through drying provides numerous benefits in addition to improved stability, including ease of handling/storage and reduction in transpor tation costs. These factors are critical in products for which: 1) a robust system (i.e., facility, equipment, validation, etc.) for maintaining the integrity and stability of the DS at low temperature during storage and transport.
All drying techniques share a common objective (i.e., removal of water), however conceptually they are different and may require modifications based on the properties of the compound. The need to preserve high product quality of labile biomolecules and maintain aseptic processing has limited the number of process technology e m p l o y e d i n t h e b i o p h a r m a c e u t i c a l i n d u s t r y.
Lyophilization is the most widely acceptable technique
for improving the stability of biopharmaceutical compounds and several commercially approved products are available [2] . As such, lyophilization represents the gold standard to which alternative drying methods must be compared.
Next Generation Drying Technologies
The choice of drying method depends on several factors including the physical properties of the product, application of the product, container closure system, type of energy source available, and scalability requirements.
The temperature at which the product is dried is one of the key parameters influencing the quality of the dried product. Typically, higher temperatures will have a negative impact on product quality while decreasing the drying time. Lower drying temperatures, on the other hand, maintain product quality, but require a lengthy drying process. Thus, optimization of the drying temperature and processing time is the most common challenge encountered in developing an efficient drying process.
Depending on the energy source and the configuration of the drying system, the parameters to be optimized will differ, as will be described below for select processing techniques. Energy consumption, quality, process yield (recovery), and shelf-life of the dried product are critical parameters assessed during the evaluation of a novel drying technology. The different techniques introduce varying stresses, which may compromise stability [3] . In addition, lessons learned and advances in drying technologies from more mature industries, such as food science, may be adapted to address the unique challenges encountered by the biopharmaceutical industry.
Spray Drying
Several spray dried food powders are commercially available in the market today, including powdered milk, whey, and egg products. The spray drying process is conceptually simple; a solution is fed through an atomizer to create a spray, which is exposed to a heated gas stream to promote rapid evaporation. When sufficient liquid mass has evaporated, the remaining solid material in the droplet forms particles which are then separated from the gas stream using a filter or a cyclone. Particle formation time is a function of the initial liquid droplet size, the composition of the droplet, and evaporation rate.
The rate of particle formation is a key parameter that dictates the required residence time and hence the scale of equipment and processing parameters required to produce the desired particle size at the target production rate. The concept has been implemented over a range of equipment scales from bench units to large multistory commercial dr ying towers. Exubera® (Nektar/Pfizer) was the first inhaled therapeutic to be successfully manufactured by spray drying [4] .
In addition to its ability to control powder properties, the key advantages of spray drying compared to conventional freeze-drying include: (1) shorter process cycle time (i.e., more batches per unit time), (2) scalability (i.e., large batch size per unit, requiring fewer production units), and (3) the ability to process at atmospheric pressure. Figure 1 shows the drastic difference in the structure and shape of freeze-dried and spray dried mango powders [5] . The spray dried preparations possessed a spherical shape and smooth surface whereas the freezedried preparations possessed a skeletal-like structure and were highly porous. The color of the spray dried mango powder was lighter compared to freeze-dried powder, which was due to an additional excipient (maltodextrin) used in the spray dried formulation. Both powders exhibited amorphous properties (i.e. no crystalline peak in the X-ray diffraction pattern) with no significant difference in the T g . The drying residence time of a few seconds for the spray dried process was significantly shorter than the drying time of the freeze-dried product ( 30 hours).
Similar to lyophilization, protein denaturation has been reported during spray drying due to desiccation-and surface-associated stresses, often necessitating the use of excipients for stabilization. Even though the drying gas temperature may exceed 100 in a typical spray drying condition, thermal denaturation of proteins is commonly not observed, mainly because the temperature of the droplet barely exceeds the wet bulb temperature of water ( 40 ) . Additionally, the protein denaturation temperature is a function of water content, increasing sharply with decreasing water content. Although one must keep in consideration the risk of prolonged particle exposure to drying gas in the collector vessel, dry proteins are relatively stable, demonstrating denaturation temperatures typically exceeding 100 [6] .
Feasibility to spray dry sucrose-based mAb formulation was assessed using lab-scale MS-35 (SPX Flow Inc., Elkridge, MD, USA) and bench-top B290 (Büchi, New
Castle, DE, USA) spray drying units. Sucrose was maintained at 50 mg/mL and protein concentration was varied between 12.5 to 83 mg/mL for two mAbs, mAb 1 and mAb 2. Process parameters were initially optimized using a placebo formulation and then adjusted throughout the production runs to maintain the desired target outlet temperature. For both mAbs, recovery decreased with increasing sucrose-to-mAb ratio (R sm ), which may be explained by the decrease in protein surface accumulation and T g ; in the case of mAb 1, recovery decreased from 90% to 53% upon increasing R sm from 0.6 to 4. For reference, the recover y from the bench-top B290
(Büchi) was 62% at 0.6 R sm with much lower throughput (i.e., 5x lower). Recovery in the absence of a surfactant was greater than that in its presence for both mAbs. In terms of storage stability, no change in % monomer was observed by size-exclusion chromatography (SEC) irrespective of R sm for mAb 1, mAb 2 formulated at 0. 6 R sm did not demonstrate any change in % monomer upon storage at 2-8 for 12 mo. At higher R sm values, however, 20% decrease in % monomer was observed.
Bowen et al. [7] evaluated the feasibility of spray drying several mAbs in a trehalose-based formulation using similar dryers. In the initial study, 95% recovery was former. This is a good counter example to the currentlyaccepted mantra of drier product leads to improved stability. The observation was more substantial at R tm of 2 than at 0.5. Work by Greiff [8] also suggests the existence of optimal residual water content for influenza virus (1 -2 %), for which the lowest water content (0.4 %) resulted in the worst stability.
In the follow-up study, Gikanga et al. [9] evaluated the Furthermore, the activity of mAb formulations postspray drying was reported to be comparable to those prior to spray drying using an in vitro potency assay.
While the examples provided above have been limited to proteins, spray drying has been utilized to successfully prepare a number of dry vaccines, including measles vaccine [11] and tuberculosis vaccine [12] . Spray dr ying represents the most mature alternative dr ying technology to lyophilization. The process provides an opportunity to engineer particle size and shape, which can enable delivery methods that are infeasible using 
Spray Freeze-Drying
Spray freeze-drying (SFD) is a drying process that involves elements of spray dr ying and freeze-dr ying.
SFD technology has been applied to a range of food products such as whey protein, maltodextrin, coffee, and milk powder [13] . However, applications may be limited to valuable food and pharmaceutical products due to the high fixed and operating costs of the freeze-drying process. The process steps involved in SFD include atomization, rapid freezing, primary drying, and secondary dry- One advantage of SFD is that sublimation and secondary drying of the frozen particles are more rapid than those encountered in conventional freeze-drying due to the increased surface area of the frozen starting material. To date, SFD has been utilized to produce several vaccines [14, 15] , solid dispersions [16] , and nanoparticles [17] .
One par ticular area in which SFD has demonstrated superiority over spray drying and freeze-drying is in the preparation of dry Alum-containing vaccines [18] .
In addition to the usual stresses experienced during freezing and drying, SFD presents additional stresses including those resulting from: 1) the shear forces experienced during atomization and 2) the exposure to the air-water interface, at which potential adsorption, unfolding, and aggregation of proteins may occur [19] . As the use of SFD results in the formation of powders possessing high specific surface area, the technology has also been utilized to promote rapid wetting and faster dissolution of poorly water soluble dr ugs [21] . Spray freeze-dried skim milk powders were reported to be highly porous and wetted three times faster in comparison to their spray dried counterparts [22] . Several mAb formulations were processed using the spray freezedryer at Meridion Technologies (Müllheim, Germany).
mAb formulation containing sucrose at 5:2 weight ratio (mAb-to-sucrose) resulted in a free-flowing pellet that was easy to aliquot and re-suspend; very short reconstitution time was achieved ( 7 min) even at the target concentration of 200 mg/mL. The impact of annealing on the reconstitution behavior was also investigated by
Webb et al. [23] ; while the annealed lyophilized cakes exhibited slower dissolution compared to the unannealed cakes (1.3 to 17.7-fold slower, depending on formulation composition), the annealed SFD samples exhibited an increase in dissolution rate compared to the corresponding un-annealed material (1.7 to 4.9-fold higher, depending on formulation composition). For the latter, the authors proposed the annealing-induced decrease in the internal surface area of the porous particles to lead to an increase in their density, thus accelerating powder submersion and dissolution.
Overall, SFD offers several advantages over lyophilization including faster dr ying times, lower energy consumption during drying, and flexibility during scaling.
Dif ficulties inherent to spray-based processes, as described above for spray drying, will need to be overcome.
Foam Drying
Foam dr ying is a desiccation process, whereby the solution is converted to a dried foam structure in a single step [24] . The overall method involves boiling, or foaming, of the solution under reduced vapor pressure followed by rapid evaporation, leaving a solidified foam structure. The product appearance is analogous to that for a formulation that has undergone extensive gross/ macro-collapse during freeze-drying [3] . The temperature is carefully controlled to avoid freezing due to evaporative cooling. Excellent vacuum control is crucial for foam drying. In addition to the processing variables, the formulation composition has been reported to affect the foaming efficiency and the subsequent storage stability of the biotherapeutics.
Benefits of foam drying include: 1) the ability to operate at near-ambient temperature, 2) the removal of water at a moderate rate, as the process is completed within hours to days, and 3) the avoidance of ice formation, which has been reported to lead to protein aggregation. Foam dried preparations demonstrated significant improvement in stability compared to those processed by spray drying or freeze-drying (Table 1) Foam dr ying does introduce its own unique set of stresses not encountered in lyophilization, namely the surface tension stress associated with cavitation. In addition, the rate of water desorption is expected to be slower for foam dried material compared to a similar formulation processed by freeze-drying. Thus, a longer secondary drying process may be required to reduce the residual water content to similar levels as that achieved by freeze-drying, which may potentially negate the energy and time savings associated with foam dr ying. While decreased secondary drying times can be achieved by increasing the drying temperature, the compound being processed should be kept in mind; for example, cell and virus viability has been repor ted to be reduced by greater than 90% with the utilization of high temperature secondar y dr ying conditions [32] . Previous examples [29, 32] highlight that increased dr ying kinetics and reduced residual water content are not always preferred from a product stability standpoint. Foam drying cycle optimization requires an understanding of the effect of drying kinetics and residual water content, as well as distribution, on product stability.
Although much research has been conducted recently on understanding the nature of foaming materials, additional challenges will need to be overcome before foam Table 1 Comparison of storage stability of H1N1 LAIV processed using freeze-drying, spray drying, and foam drying. 
Microwave-Assisted Drying
Microwaves are commonplace in ever yday use for heating food, however their application at the industrial scale may be unfamiliar to most. Microwave drying is based on the absorption of microwave radiation by water molecules leading to vaporization [33] . One of the main advantages of microwave-assisted drying is the reduction of drying time. This is in part attributed to its unique supply of energy. In microwave drying, heat is supplied volumetrically by high frequency polarization of dipole molecules, in comparison to infrared and convective drying for which energy is supplied to the surface of material. Other notable advantages include efficient energy conversion, improved and more rapid process control, and uniform heating (assuming a uniform distribution of the microwave field) [34] . In recent years, microwave drying has been combined with vacuum-and freeze-drying to obtain food and pharmaceutical products of acceptable quality [35, 36] .
Microwave-assisted vacuum drying (MVD) combines the rapid heating, high efficiency, and control of microwave drying with improved efficiency from the lowering of the boiling point of water under vacuum [37] . Figure 2 illustrates the residual water content (%, wet basis)-ver- Microwave-assisted freeze-dr ying (MFD) utilizes microwaves as the heat source to enable sublimation in the freeze-dr ying process [42] . Compared to conventional freeze-drying, MFD has a much greater drying efficiency and reduced energy consumption. The freezedrying process time of cabbage has been reduced by half utilizing MFD while maintaining similar product quality [43] . Durance et al. [44] reported the feasibility to dry a 10% lysozyme solution to 2-5% residual water content with a dehydration time of 27 minutes using MFD. There was no change in the lysozyme enzymatic activity before and after dehydration.
For heat-sensitive products, such as labile biopharmaceuticals, the exposure to microwave radiation may need to be limited. While microwave-assisted drying technologies can provide substantial benefit to reducing drying times, their ability to stabilize biopharmaceuticals without microwave-induced product damage will need to be demonstrated. In addition, significant changes in drying kinetics, as well as potential alterations in the distribution of water, may impact product quality and stability. as infrared radiation [45] and acoustic waves [46] . As the sensitivity of pharmaceuticals is unique to the given compound, the selected drying technique may not be universally applicable. By understanding the dr ying mechanisms and the unique stresses involved, the drying techniques can be and should be tailored for use (e.g., hybrid 
